Thursday, October 30 7:30–9:15am
P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 (Part 1)
Thursday, October 30 10:15am–12:30pm
P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 (Part 2)
Wednesday, October 29 8:30–9:30am
Brain Check: Promoting Brain Health and Detecting Cognitive Impairment
Wednesday, October 29 8:30–9:30am
Brain Check: Promoting Brain Health and Detecting Cognitive Impairment
Thursday, October 30 7:30–9:15am
P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 (Part 1)
Thursday, October 30 10:15am–12:30pm
P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 (Part 2)
Wednesday, October 29 3:30–4:15pm
Thursday, October 30 7:30–9:15am
P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 (Part 1)
Thursday, October 30 10:15am–12:30pm
P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 (Part 2)
Thursday, October 30 7:30–9:15am
P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 (Part 1)
Thursday, October 30 10:15am–12:30pm
P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 (Part 2)
Thursday, October 30 1:30–2:30pm
Bridging the Gap: Addressing Health Disparities in Dermatologic Conditions
Thursday, October 30 2:45–3:30pm
Pharmacology Updates 2025: New Medications Reshaping Primary Care
Wednesday, October 29 11:30am–12:30pm
AI - The Good, The Bad, and The Ugly (Navigating the New Reality of AI in Medicine)
Wednesday, October 29 4:30–6pm
Taking the Dialogue to the Next Level: Facilitating Open Communication About Obesity
Wednesday, October 29 7:30–8:30am
Wednesday, October 29 4:30–6pm
Taking the Dialogue to the Next Level: Facilitating Open Communication About Obesity
Wednesday, October 29 1:30–2:30pm
Cardiology in Focus: Breaking Down the Latest Guideline Updates
Disclosures
The following financial relationships have been disclosed by faculty, and all have been mitigated by Pri-Med Institute. Relevant relationships will be disclosed at the start of each presentation.
Financial Disclosures
- Charles E. Argoff, MD, FABPM
- Information to come
- Andrew E. Budson, MD
- Eli Lilly and AbbVie, Advisor; Vox Neuro and Bristol Meyers Squibb, Independent Contractor
- Amy Clouse, MD, FAAFP
- Astellas Pharmacueticals, Speaker; Eli Lilly; Novo Nordisk, Stock Holder (publicly traded company)
- Oscar A. de Leon-Casasola, MD
- Information to come
- Stephanie Faubion, MD, MBA, FACP, NCMP, IF
- Information to come
- Katherine E. Galluzzi, DO, CMD, FACOFP
- Lilly, Advisor
- Aubrey J. Grant, MD, FACC
- Information to come
- Gregory L. Hall, MD
- No relevant financial relationships disclosed
- Lawrence Herman, DMSc, MPA, PA-C, DFAAPA
- Novo Nordisk, Speaker
- Peter Lin, MD, CCFP
- Information to come
- Joynita R. Nicholson, DO, DABOM, FOMA
- No relevant financial relationships disclosed.
- Philip Schoenfeld, MD, MSEd, MSc
- Ironwood Pharmaceuticals, Ardelyx Pharmaceuticals, Phathom Pharmaceuticals, AbbVie Pharmaceuticals, Speaker; Phathom Pharmaceuticals, Ardelyx Pharmaceuticals, Consultant
- Charles Vega, MD, FAAFP
- Boehringer Ingelheim, and Exact Sciences, Consultant
- Karol E. Watson, MD, PhD
- Amarin, Consultant; Amgen, Consultant; Boehringer Ingelheim, Consultant; Eli Lilly, Consultant; Novartis, Consultant
- Laila Woc-Colburn, MD
- No relevant financial relationships disclosed.
Other Disclosures
Pamela Kushner, MD, FAAFP (Reviewer): Speaker and Advisor for AstraZeneca, Boehringer Ingelheim, Corcept, GSK, Haleon, and Novo Nordisk; Speaker for Astellas, Bayer, Janssen, Lilly, and Phathom; Advisor for Abbott and Bausch/SALIX
All other non-faculty contributors involved in the moderating, planning, development, editing and review of the content have disclosed no relevant financial relationships.